Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Aug 15, 2026
Destiny Tech100 Inc. (DXYZ) Delivers +17.9% Gain in 30 Days Amid Private Tech Rebound

Destiny Tech100 Inc. (DXYZ) Delivers +17.9% Gain in 30 Days Amid Private Tech Rebound

Key Takeaways

  • Destiny Tech100 Inc. (DXYZ) rose approximately 17.9% over the last 30 days, moving from a closing price near $27.15 to $32.00 in the latest completed session.
  • The fund remains about 33% lower over the trailing three-month window, underscoring a volatile stretch that included a sharp run-up into the SpaceX public debut and a subsequent sell-off.
  • Portfolio exposure is concentrated in private technology leaders, including Anthropic, SpaceX, OpenAI, Shield AI, Databricks, and other venture-backed names.
  • Renewed demand for diversified pre-IPO technology exposure, supported by confidential IPO filings from Anthropic and OpenAI, has been a central driver of the rebound.
  • As a closed-end fund, DXYZ can trade at a material premium or discount to its net asset value, adding structural risk beyond the underlying portfolio.

A Closer Look at Destiny Tech100 Inc. (DXYZ) and Its Holdings

Destiny Tech100 Inc. is a non-diversified, closed-end management investment company listed on the NYSE. Its investment objective is to maximize total return principally through capital gains on equity and equity-related investments. Under normal market conditions, the fund invests at least 80% of total assets in technology-sector companies, with an emphasis on rapidly growing, venture-capital-backed emerging companies primarily located in the United States. The fund intends to build toward roughly 100 positions over time.

The portfolio currently holds approximately 32 private technology companies. Recent disclosures show Anthropic at about 18.1% of economic exposure, SpaceX-related interests collectively near 14.5%, and OpenAI around 5.8%. Additional positions include Shield AI, Databricks, Tenstorrent, Revolut, Axiom Space, and several other private-market names, alongside a meaningful cash position. The gross expense ratio—annual operating costs as a percentage of assets—is 4.98%, which is materially higher than most passive exchange-traded fund (ETF) structures. Because DXYZ is a closed-end fund, its share price reflects market demand as well as the value of its holdings. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.

Recent Price Action in DXYZ: 30 Days Versus the Quarter

Over the last 30 days, DXYZ advanced approximately 17.9%, rising from a close near $27.15 to $32.00 in the latest completed session. The move was not a steady climb: shares traded into the low $20s in late July before rallying more than 50% into mid-August. This is best characterized as a high-volatility rebound rather than a gradual trend.

Over the trailing three-month window, the fund is down about 32.8%, using a starting close near $47.62. The quarter captured a powerful surge into the SpaceX initial public offering (IPO), a pronounced sell-the-news unwind, and the recent recovery. Price swings were extreme, with the share price ranging from the low $20s to above $70 during the period. That volatility is consistent with a closed-end fund whose daily price reflects both portfolio fundamentals and shifting investor sentiment.

What Supported the Recent Advance in DXYZ

The recent advance reflects renewed enthusiasm for private artificial intelligence and space assets. SPCX began trading publicly in June and traded strongly after its debut, refocusing attention on the remaining pre-IPO companies inside the DXYZ portfolio. Anthropic and OpenAI each moved closer to potential public listings through confidential IPO filings, reinforcing demand for diversified vehicles that already hold these companies.

As the largest disclosed position, Anthropic has been a central influence on the rebound, while OpenAI and the fund's remaining SpaceX exposure amplified the move. Positioning also contributed: short interest declined sharply from elevated mid-June levels into mid-July, reducing a potential supply overhang. The result was a sentiment-driven recovery in a fund whose performance remains tightly linked to private-market technology narratives. From what I see, this kind of rebound often benefits from broader sentiment shifts around pre-IPO names.

The Drivers Behind the Quarterly Decline

The three-month decline is largely a story of the SpaceX proxy trade. In the weeks before SpaceX listed, DXYZ rallied as investors sought pre-IPO exposure. Once SpaceX became directly tradable, part of the scarcity premium faded and the fund sold off sharply. Premium compression was amplified by the fund's own share issuance profile and by profit-taking after an exceptionally strong run.

Longer term, the quarter illustrates how closed-end fund prices can detach from net asset value (NAV). The underlying portfolio has benefited from rising valuations across private AI and space companies, but the share price has been driven more by IPO calendar sentiment, supply and demand for listed shares, and the changing appeal of proxy exposure after a major holding becomes public.

What Investors Should Watch Next With DXYZ

Investors should monitor the IPO calendar as the next major catalyst. Anthropic and OpenAI have confidentially filed for public listings, and their pricing, timing, and aftermarket trading will directly influence sentiment toward DXYZ. SpaceX's post-IPO performance and any lockup expirations will also matter, since the fund retains meaningful SpaceX exposure.

Beyond single names, the fund's NAV disclosures and premium or discount to NAV will be important. Additional at-the-market share sales could pressure the listed price, while new venture funding rounds or markups in core holdings could support NAV growth. Macroeconomic conditions, interest rate expectations, and risk appetite for speculative technology exposure will continue to shape demand. Regulatory developments affecting private-market access, AI governance, or closed-end fund distribution would also be relevant. The central risk is structural: DXYZ can remain volatile even when the underlying portfolio is stable, because its listed price is influenced by flows, sentiment, and supply dynamics. I’m watching this closely as the IPO timeline unfolds.

Using AI Tools in My Research Process

In my work analyzing funds like this, I frequently rely on Tickeron’s AI Screener to scan for comparable vehicles and evaluate technical and fundamental characteristics side by side. The platform helps narrow results using volatility measures, price patterns, and industry filters, which can save time when monitoring thematic exposure. It has become a regular part of refining watchlists and confirming relative strength in volatile names. Explore the AI Screener to build data-driven watchlists and refine your security selection workflow.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DXYZ

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


Momentum Indicator for DXYZ turns positive, indicating new upward trend

DXYZ saw its Momentum Indicator move above the 0 level on August 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator turned positive. In of the 39 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

DXYZ moved above its 50-day moving average on August 11, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DXYZ advanced for three days, in of 114 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for DXYZ moved below the 200-day moving average on August 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXYZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DXYZ broke above its upper Bollinger Band on August 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for DXYZ entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Industry description

Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It is designed to be an investment portfolio of the Top 100 High-Growth Tech Companies.
View a ticker or compare two or three
DXYZ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Unknown

Profile
Details
Category
Technology
Address
N/A
Phone
N/A
Web
N/A
Interact to see
Advertisement
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Golar LNG (GLNG) has remained resilient in recent trading, hovering near the top of its 52-week range as investor interest in floating LNG infrastructure continues to build. The stock is underpinned by a deep FLNG order backlog, steady production from operating assets, and improving financial flexibility.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Cincinnati Financial (CINF) reports Q4 2025 earnings on February 9, 2026, after market close, with consensus EPS of $2.86–$2.89 and revenue around $2.91 billion. Allstate (ALL) recently reported Q4 2025 EPS of $14.31, well above the $8.72 estimate, with revenue of $17.3 billion on February 4, 2026.
Coca-Cola (KO) reports Q4 2025 earnings on February 10, 2026, with consensus EPS of $0.56 and revenue of $12.05 billion. PepsiCo (PEP) beat Q4 2025 estimates on February 3, reporting adjusted EPS of $2.26 (vs. $2.24 expected) and revenue of $29.34 billion.
(AZN) AstraZeneca’s full-year 2025 results, set for February 10, 2026, cap a year of sustained growth amid competitive pressures. Following 21% total revenue growth in FY 2024 and 19% core EPS expansion, AZN has maintained momentum with 11% revenue growth through nine months of 2025. The report offers insight into:
Gilead Sciences (GILD): Q4 2025 earnings due February 10, consensus EPS $1.83, revenue $7.68B. Growth driven by HIV franchise; oncology investments like Trodelvy may offer upside. Amgen (AMGN): Reported Q4 2025 EPS $5.29 vs $4.73 expected, revenue $9.9B (+9% YoY). Strong 2026 guidance: $37–38.4B revenue, $21.60–23.00 non-GAAP EPS.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Destiny Tech100 Inc. (DXYZ) Delivers +17.9% Gain in 30 Days Amid Private Tech Rebound